Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients.
about
Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Interim analysis of a phase I/ ...... d endometrial cancer patients.
@en
Interim analysis of a phase I/ ...... d endometrial cancer patients.
@nl
type
label
Interim analysis of a phase I/ ...... d endometrial cancer patients.
@en
Interim analysis of a phase I/ ...... d endometrial cancer patients.
@nl
prefLabel
Interim analysis of a phase I/ ...... d endometrial cancer patients.
@en
Interim analysis of a phase I/ ...... d endometrial cancer patients.
@nl
P2093
P2860
P356
P1433
P1476
Interim analysis of a phase I/ ...... d endometrial cancer patients.
@en
P2093
Alfred F Trappey
Chad A Hamilton
Diane F Hale
Doreen O Jackson
Erika J Schneble
G T Clifton
Garth S Herbert
George E Peoples
George L Maxwell
John C Elkas
P2860
P304
15912-15923
P356
10.18632/ONCOTARGET.13305
P407
P577
2016-11-11T00:00:00Z